Symptomatic obstructive hypertrophic cardiomyopathy

Myosin inhibition is considered a key therapeutic approach in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). In addition to mavacamten, aficamten is now being clinically investigated as a potentially short-acting, specific myosin inhibitor. The FOREST-HCM study provides the first systematically collected 48-week data on efficacy, safety and functional changes under long-term treatment. The results provide relevant insights into the stability of gradient reduction, symptom control and tolerability of the drug in continuous use.